OptiNose presents fluticasone study results
The results showed that administering fluticasone with OptiNose’s device is effective in the treatment of refractory CRS, with significant and clinically relevant improvements compared with placebo in both
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.